Kiwalkar, Sonam http://orcid.org/0000-0002-9507-9617
Howard, Richard http://orcid.org/0000-0002-8589-1409
Choi, Dongseok http://orcid.org/0000-0002-1552-4072
Deodhar, Atul http://orcid.org/0000-0002-2130-1246
Article History
Received: 10 June 2022
Revised: 7 June 2023
Accepted: 8 June 2023
First Online: 22 June 2023
Compliance with ethical standards
:
: All study participants provided their consent for participation. Consent forms are available upon request.
: SK declares that she has no competing interests. RH declares that he has the following competing interests: C<i>onsulting/advisory board:</i> Novartis, GSK; <i>Stock:</i> AbbVie, Amgen, Bristol Myers Squibb, GSK, Johnson & Johnson, Lilly, Merck, Novartis, Pfizer, Teva, UCB, Viatris. DC declares that he has no competing interests. AD declares that he has the following competing interests: <i>Consulting/advisory boards:</i> AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, GSK, Eli Lilly, Janssen, Novartis, Pfizer, UCB; <i>Research grants:</i> AbbVie, Lilly, Novartis, Pfizer, UCB.
: UCB did not participate in the survey design, interpretation of results, or manuscript development.